MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 05.03.2026
Lexicon Pharmaceuticals Langfristiger Schuldenstrom 2011-2026 | LXRX
Langfristiger Schuldenstrom Jährlich Lexicon Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.64 M | 1.18 M | 1.29 M | 1.29 M | 1.09 M | 553 K | 11 M | 1.12 M | 14.1 M | 16.3 M | 2.02 M | 20.2 M | 1.71 M | 1.57 M | 1.44 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 20.2 M | 553 K | 5.1 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Heron Therapeutics
HRTX
|
3.04 M | $ 0.8 | 2.7 % | $ 133 M |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 19.23 | -1.38 % | $ 899 M | USA |
 |
Altimmune
ALT
|
256 K | $ 3.44 | 2.99 % | $ 303 M | USA |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.63 | 0.77 % | $ 16.5 M | USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Ascendis Pharma A/S
ASND
|
14.2 M | $ 218.06 | -1.72 % | $ 5 B |  Danmark |
 |
Incyte Corporation
INCY
|
5.7 M | $ 90.45 | -0.36 % | $ 17.7 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Inovio Pharmaceuticals
INO
|
2.41 M | $ 1.61 | 1.9 % | $ 35.7 M | USA |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | Canada |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
780 K | $ 12.84 | 0.78 % | $ 774 M | USA |
 |
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | USA |
 |
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
KalVista Pharmaceuticals
KALV
|
1.98 M | $ 16.6 | -2.35 % | $ 824 M |  Britain |
 |
Kamada Ltd.
KMDA
|
2.12 M | $ 8.2 | -0.61 % | $ 260 M | Israel |
 |
Calithera Biosciences
CALA
|
1.37 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
1.92 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
2.81 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | USA |
 |
Karyopharm Therapeutics
KPTI
|
438 K | $ 6.66 | -12.71 % | $ 812 K | USA |
 |
Keros Therapeutics
KROS
|
2.41 M | $ 11.24 | 2.55 % | $ 418 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Longeveron
LGVN
|
655 K | $ 0.95 | -2.71 % | $ 16.7 B | USA |
 |
Denali Therapeutics
DNLI
|
8.31 M | $ 21.09 | 4.56 % | $ 3.47 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
425 K | $ 4.42 | 4.25 % | $ 734 M | Canada |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |